# Treatment of Schizophrenic Patients With Ziprasidone

> **NCT00579670** · — · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 450 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Ziprasidone

## Key facts

- **NCT ID:** NCT00579670
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2021-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00579670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00579670, "Treatment of Schizophrenic Patients With Ziprasidone". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00579670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*